Sinotherapeutics (SH:688247) 智通财经网·2026-02-27 09:08Core Viewpoint - Xuantai Pharmaceutical (688247.SH) reported a decline in both revenue and net profit for the fiscal year 2025, primarily due to market pressures from national drug procurement policies and increased competition in the U.S. market [1] Financial Performance - The company achieved total operating revenue of 446.49 million yuan, a year-on-year decrease of 12.73% [1] - The net profit attributable to the parent company's shareholders was 48.95 million yuan, reflecting a significant year-on-year decline of 61.67% [1] Key Reasons for Performance Decline - The implementation of the 10th batch of national drug procurement led to overall market price pressures, affecting the profitability of the company's product, Posaconazole enteric-coated tablets, despite not being selected in this procurement round [1] - In the U.S. market, sales and profitability of Mesalamine enteric-coated tablets decreased year-on-year due to an increase in approved generic manufacturers and rising tariffs [1] - The company adopted a cautious approach by recognizing impairment losses on accounts receivable, inventory, and goodwill in accordance with relevant accounting standards, negatively impacting the current net profit [1]